{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-125872","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.434728+00:00","generated_at":"2026-06-07T12:32:55.039952+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Glaukos receives FDA approval for iDose TR; 2024 revenue guidance $350-$360M","bullets":["FDA approved iDose TR (travoprost intracameral implant) for reducing IOP in OHT or OAG; launch expected late Q1 2024.","Phase 3 trials randomized 1,150 subjects; iDose TR showed non-inferiority to timolol at 3 months (IOP reduction 6.6-8.4 mmHg).","81% of iDose TR subjects were free of topical IOP-lowering medications at 12 months; 98% subject retention at 12 months.","Wholesale acquisition cost set at $13,950 per implant; Glaukos launches iDose Your Dose charitable donation initiative.","Reaffirms 2023 net sales guidance of $307-$310M; introduces 2024 preliminary guidance of $350-$360M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-125872","json":"https://secwatch.observer/filing/0001104659-23-125872.json","markdown":"https://secwatch.observer/filing/0001104659-23-125872.md","text":"https://secwatch.observer/filing/0001104659-23-125872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000110465923125872/0001104659-23-125872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000110465923125872/tm2332871d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:32:55.039952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}